Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biochemical Pharmacology

• Publication date

  2005-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.BCP.2005.05.011PMID 15963472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis

  2005cited by this paper
• Structure and function of fatty acid amide hydrolase.

  2005cited by this paper
• Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation

  2005cited by this paper
• A new strategy to block tumor growth by inhibiting endocannabinoid inactivation

  2004cited by this paper
• The endogenous cannabinoid system protects against colonic inflammation.

  2004cited by this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle.

  2004cited by this paper
• Anandamide transport.

  2004cited by this paper
• Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity

  2004cited by this paper
• Endocannabinoid transport tightly controls 2‐arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404

  2004cited by this paper
• In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake.

  2004cited by this paper
• Novel selective and metabolically stable inhibitors of anandamide cellular uptake.

  2003cited by this paper
• The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy

  2003cited by this paper
• Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

  2003cited by this paper
• Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

  2003cited by this paper
• Cellular accumulation of anandamide: consensus and controversy

  2003cited by this paper
• CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

  2003cited by this paper
• Modulation of anxiety through blockade of anandamide hydrolysis

  2003cited by this paper
• An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice.

  2003cited by this paper
• Possible endocannabinoid control of colorectal cancer growth.

  2003cited by this paper
• UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide.

  2002cited by this paper
• Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission

  2002cited by this paper
• Endocannabinoids as physiological regulators of colonic propulsion in mice.

  2002cited by this paper
• A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation.

  2002cited by this paper
• Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

  2002cited by this paper
• Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance.

  2002cited by this paper
• The endogenous cannabinoid system controls extinction of aversive memories

  2002cited by this paper
• Endocannabinoids control spasticity in a multiple sclerosis model

  2001cited by this paper
• The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors.

  2001cited by this paper
• Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.

  2001cited by this paper
• Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.

  2000cited by this paper
• Carrier‐mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‐arachidonylglycerol

  2000cited by this paper
• Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity

  2000cited by this paper
• Structure—Activity Relationships Among N‐Arachidonylethanolamine (Anandamide) Head Group Analogues for the Anandamide Transporter

  2000cited by this paper
• The anandamide transport inhibitor AM404 activates vanilloid receptors.

  2000cited by this paper
• The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide.

  1998cited by this paper
• Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.

  1998cited by this paper
• A second endogenous cannabinoid that modulates long-term potentiation

  1997cited by this paper
• Biosynthesis of 2-arachidonoyl-glycerol, a novel cannabimimetic eicosanoid, in mouse neuroblastoma cells.

  1997cited by this paper
• 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.

  1995cited by this paper
• Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines.

  1995cited by this paper
• Occurrence and postmortem generation of anandamide and other long‐chain N‐acylethanolamines in mammalian brain

  1995cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper

• Early biomarkers in the presymptomatic phase of cognitive impairment: changes in the endocannabinoidome and serotonergic pathways in Alzheimer's-prone mice after mTBI

  2024cites this paper
• The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases

  2022cites this paper
• Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants

  2022cites this paper
• Lipid endocannabinoids in energy metabolism, stress and developmental programming.

  2021cites this paper
• Dipiron farelerde anksiyolitik-benzeri etkiler oluşturuyor mu?

  2019cites this paper
• Endocannabinoid and N-acylethanolamide levels in rat brain and spinal cord following systemic dipyrone and paracetamol administration.

  2019cites this paper
• New approaches and challenges to targeting the endocannabinoid system

  2018cites this paper
• Endocannabinoidome

  2018cites this paper
• Anticonvulsant and Neuroprotective Effects of Cannabidiol During the Juvenile Period

  2018cites this paper
• Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice.

  2018cites this paper
• The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.

  2017cites this paper
• Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation

  2017cites this paper
• Ferulic acid, a phenolic compound with therapeutic effects in neuropsychiatric disorders, stimulates the production of nerve growth factor and endocannabinoids in rat brain

  2017cites this paper
• Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis.

  2016cites this paper
• Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys

  2016cites this paper
• From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology.

  2016cites this paper
• The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders

  2016cites this paper
• Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems—A Novel Treatment Option for Chronic Pain Management

  2016cites this paper
• Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.

  2016cites this paper
• N-Acyldopamines and N-Acylserotonins: From Synthetic Pharmacological Tools to Endogenous Multitarget Mediators

  2015cites this paper
• Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner

  2015cites this paper
• The Endocannabinoid Signaling System in the CNS: A Primer.

  2015cites this paper
• Possible inhibitory role of endogenous 2-arachidonoylglycerol as an endocannabinoid in (±)-epibatidine-induced activation of central adrenomedullary outflow in the rat.

  2015cites this paper
• Acute Resistance Exercise Induces Antinociception by Activation of the Endocannabinoid System in Rats

  2014cites this paper
• Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.

  2014cites this paper
• Role of the Endocannabinoid System in Extinction of Learned Behaviours Motivated by Opioid-Induced Reward and Aversion in Rats

  2013cites this paper
• Role of the Cannabinoid System in Modulating the Reinforcing and Relapse Related Properties of Nicotine in Rats

  2013cites this paper
• Endocannabinoid function in hippocampal synaptic plasticity and spatial working memory

  2013cites this paper
• Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential

  2013cites this paper
• An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH).

  2013cites this paper
• Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism

  2013cites this paper
• Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study.

  2012cites this paper
• The CB1 Receptor-Mediated Endocannabinoid Signaling and NGF: The Novel Targets of Curcumin

  2012cites this paper
• "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.

  2012cites this paper
• The Role of the Endocannabinoids in Suppression of the Hypothalamic-pituitary-adrenal Axis Activity by Doxepin

  2011cites this paper
• Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists.

  2011cites this paper
• The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs

  2011cites this paper
• Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract.

  2011cites this paper
• Endogenously generated 2-arachidonoylglycerol plays an inhibitory role in bombesin-induced activation of central adrenomedullary outflow in rats.

  2011cites this paper
• Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls

  2010cites this paper
• Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.

  2010cites this paper
• THEMED ISSUE: CANNABINOIDS REVIEW Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls

  2010cites this paper
• The Role of Cannabinoid Receptors in the Descending Modulation of Pain

  2010cites this paper
• Activity-based anorexia in C57/BL6 mice: effects of the phytocannabinoid, Delta9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2.

  2010cites this paper
• Endocannabinoid signaling in neurotoxicity and neuroprotection.

  2010cites this paper
• Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.

  2010cites this paper
• The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice.

  2010influential citation
• Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs.

  2010cites this paper
• Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain

  2010cites this paper
• Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.

  2010influential citation
• Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels

  2009cites this paper
• Sleep-inducing factors.

  2009cites this paper
• The endocannabinoid system and pain.

  2009cites this paper
• The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1

  2009cites this paper
• Biochemical and Biological Properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase

  2009cites this paper
• Gender‐dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system

  2008cites this paper
• FAAH and anandamide: is 2-AG really the odd one out?

  2008cites this paper
• Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex.

  2008cites this paper
• Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.

  2008cites this paper
• Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation

  2008cites this paper
• Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis.

  2008cites this paper
• Endocannabinoids: synthesis and degradation.

  2008cites this paper
• Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum

  2008cites this paper
• The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain.

  2008cites this paper
• Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase.

  2007cites this paper
• Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors

  2007cites this paper
• Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology.

  2007cites this paper
• Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats.

  2007cites this paper
• Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain

  2007cites this paper
• Endothelium‐dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2‐arachidonoylglycerol

  2007cites this paper
• Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.

  2007cites this paper
• The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L‐29) on pain behaviour in rodent models of neuropathy

  2007cites this paper
• Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo

  2007cites this paper
• Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.

  2007cites this paper
• Endocannabinoids and the regulation of their levels in health and disease

  2007cites this paper
• Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors

  2006cites this paper
• Protective activation of the endocannabinoid system during ischemia in dopamine neurons.

  2006cites this paper
• Tolerance to cannabinoid response on the myenteric plexus of guinea‐pig ileum and human small intestinal strips

  2006cites this paper
• Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.

  2006cites this paper
• Endocannabinoidi e Fitocannabinoidi nel Cancro

  2006cites this paper
• Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.

  2006cites this paper
• Cannabinoids, opioids and eating behavior: the molecular face of hedonism?

  2006cites this paper
• Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain

  2006cites this paper
• Development of the first potential covalent inhibitors of anandamide cellular uptake.

  2006cites this paper
• Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats.

  2006cites this paper